RESPUESTA AL COMENTARIO SOBRE 'LA GOTA, UNA ENFERMEDAD METABÓLICA ACTUAL: COMORBILIDADES Y NUEVAS TERAPIAS”
Palabras clave:
GOUT, ABCG2, THERAPIES##plugins.generic.pfl.publicationFactsTitle##
##plugins.generic.pfl.reviewerProfiles## N/D
##plugins.generic.pfl.authorStatements##
Indexado: {$indexList}
-
##plugins.generic.pfl.indexedList##
- ##plugins.generic.pfl.editorAndBoard##
- ##plugins.generic.pfl.profiles##
- ##plugins.generic.pfl.academicSociety##
- N/D
Para obtener más información sobre un dato, haga clic
##plugins.generic.pfl.maintainedByPKP##
Citas
Guía de Práctica Clínica para el Manejo de Pacientes con Gota – GuíaSalud
Howren, A., et al., eHealth-supported decentralized multi-disciplinary care for gout involving rheumatology, pharmacy, and dietetics: proof-of-concept study. Clin Rheumatol, 2020. 39(4): p. 1241-1249.
New Webinar: A Multidisciplinary Approach to Managing Gout - Gout Education
Punzi, L., et al., The role of architectural design for rheumatic patients' wellbeing: the point of view of Environmental Psychology. Reumatismo, 2020. 72(1): p. 60-66.
Punzi, L. and G. Medea, Understanding and perceptions of gout: an interdisciplinary assessment among patients, physicians and pharmacists in Italy. Reumatismo, 2020. 72(1): p. 31-43.
Park, E.H., T. O'Donnell, and J. Fritz, Dual-Energy Computed Tomography Applications in Rheumatology. Rheum Dis Clin North Am, 2025. 51(2): p. 361-382.
Sirotti, S., et al., Imaging of crystal-induced arthropathies in 2025. Best Pract Res Clin Rheumatol, 2025: p. 102063.
Chou, H., T.Y. Chin, and W.C. Peh, Dual-energy CT in gout - A review of current concepts and applications. J Med Radiat Sci, 2017. 64(1): p. 41-51.
Natsuko, P.D., et al., Differential gene expression of ABCG2, SLC22A12, IL-1beta, and ALPK1 in peripheral blood leukocytes of primary gout patients with hyperuricemia and their comorbidities: a case-control study. Eur J Med Res, 2022. 27(1): p. 62.
Clavijo-Cornejo, D., O. Hernandez-Gonzalez, and M. Gutierrez, The current role of NLRP3 inflammasome polymorphism in gout susceptibility. Int J Rheum Dis, 2021. 24(10): p. 1257-1265.
Dong, Z., et al., Epistatic interaction between PKD2 and ABCG2 influences the pathogenesis of hyperuricemia and gout. Hereditas, 2020. 157(1): p. 2.
Hoque, K.M., et al., The ABCG2 Q141K hyperuricemia and gout associated variant illuminates the physiology of human urate excretion. Nat Commun, 2020. 11(1): p. 2767.
Lu, X., et al., IL-1beta functionally attenuates ABCG2 and PDZK1 expression in HK-2 cells partially through NF-kB activation. Cell Biol Int, 2019. 43(3): p. 279-289.
Notsu, T., et al., Inhibition of the uric acid efflux transporter ABCG2 enhances stimulating effect of soluble uric acid on IL-1beta production in murine macrophage-like J774.1 cells. Hypertens Res, 2023. 46(10): p. 2368-2377.
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2025 Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
© Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra under a Creative Commons Attribution 4.0 International (CC BY 4.0) license which allows to reproduce and modify the content if appropiate recognition to the original source is given.
